Media

Novartis statement on Zolgensma

Novartis stands behind Zolgensma® for the treatment of children less than 2 years of age with spinal muscular atrophy.

Novartis Financial Results – Q2 2019

Novartis announced the company’s financial results for the second quarter and first half of 2019.

Video - Novartis Financial Results

Our Executive Team talks about innovation highlights from the second quarter of 2019.

Watch video

Latest media releases

Aug 19, 2019

Novartis to present new Entresto HFpEF and HFrEF data at ESC Congress 2019
Aug 09, 2019

Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case
Aug 07, 2019

Novartis stands behind Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy
Jul 31, 2019

Novartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trials

News archive

Subscribe to media releases

Resources

Media Library

Browse and download multimedia resources including images, videos, infographics and more.

Visit the Media Library

Novartis Annual Review 2018

The Annual Review, our new corporate report, explains who we are and what we do, and highlights our progress against the company’s five strategic priorities in 2018.

Read the Annual Review

A healthcare professional speaks to a patient

Corporate Responsibility

Learn more about our Corporate Responsibility strategy and access resources including the annual Novartis in Society Report

Learn more

Corporate Fact Sheets

The fact sheets provide a comprehensive overview of Novartis overall as well as our divisions and our research organization. It also outlines our commitment to associates and to corporate responsibility.

View Fact Sheets

Social media